Research
Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to GLP-1 receptor agonists.
Tirzepatide is a newer injection that works on two hormones to lower blood sugar and lose more weight than older GLP-1 drugs.
StrongSupportsVERY_HIGH confidence
Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists.
Why this rating
Supported by the SURPASS clinical trial program.
Source
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong et al. · The Kaohsiung Journal of Medical Sciences · 2024
narrative_reviewCited 49×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →